Chromogenic in Situ Hybridization Compared with Other Approaches to Evaluate HER2/neu Status in Breast Carcinomas

Overview

Journal Braz J Med Biol Res

Specialties Biology
General Medicine

Date 2013 Apr 6

PMID 23558859

Citations 16

Authors

F E Rosa

R M Santos

S R Rogatto

M A C Domingues

Affiliations

Soon will be listed here.

Abstract

Human epidermal growth factor receptor 2 (HER2) has been evaluated in breast cancer patients to identify those most likely to benefit from herceptin-targeted therapy. HER2 amplification, detected in 20-30% of invasive breast tumors, is associated with reduced survival and metastasis. The most frequently used technique for evaluating HER2 protein status as a routine procedure is immunohistochemistry (IHC). HER2 copy number alterations have also been evaluated by fluorescence in situ hybridization (FISH) in moderate immunoexpression (IHC 2+) cases. An alternative procedure to evaluate gene amplification is chromogenic in situ hybridization (CISH), which has some advantages over FISH, including the correlation between HER2 status and morphological features. Other methodologies have also been used, such as silver-enhanced in situ hybridization (SISH) and quantitative real-time RT-PCR, to determine the number of HER2 gene copies and expression, respectively. Here we will present a short and comprehensive review of the current advances concerning HER2 evaluation in human breast cancer.

Citing Articles

Diagnosis of hydatidiform moles using and : A retrospective study.

Akbarzadeh-Jahromi M, Taheri T, Sari Aslani F, Safaei A, Pouraminaee F, Zare M Int J Reprod Biomed. 2024; 22(9):727-738.

PMID: 39618719 PMC: 11602739. DOI: 10.18502/ijrm.v22i9.17478.

HER2 in Gastric Cancer: A Comprehensive Analysis Combining Meta-Analysis and DCE-MRI Radiomics.

Shen L, Li Y, Huang H, Lu Z, Chen B Cancer Control. 2024; 31:10732748241293699.

PMID: 39448273 PMC: 11528791. DOI: 10.1177/10732748241293699.

Consensus Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2)-Low Testing in Breast Cancer in Malaysia.

Rajadurai P, Ravindran S, Lee B, Md Pauzi S, Chiew S, Teoh K Cancers (Basel). 2024; 16(13).

PMID: 39001387 PMC: 11240573. DOI: 10.3390/cancers16132325.

The Evaluation of , and in Orofacial Cleft Tissue.

Goida J, Pilmane M Children (Basel). 2022; 9(4).

PMID: 35455561 PMC: 9032315. DOI: 10.3390/children9040516.

Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored Therapies in Solid Tumors.

Chrzanowska N, Kowalewski J, Lewandowska M Molecules. 2020; 25(8).

PMID: 32316657 PMC: 7221545. DOI: 10.3390/molecules25081864.

References

Van de Vijver M, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F . Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. Breast Cancer Res. 2007; 9(5):R68. PMC: 2242665. DOI: 10.1186/bcr1776. View

Park K, Han S, Kim J, Kim H, Kwon J, Gwak G . Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer. J Breast Cancer. 2012; 14(4):276-82. PMC: 3268923. DOI: 10.4048/jbc.2011.14.4.276. View

Sinczak-Kuta A, Tomaszewska R, Rudnicka-Sosin L, Okon K, Stachura J . Evaluation of HER2/neu gene amplification in patients with invasive breast carcinoma. Comparison of in situ hybridization methods. Pol J Pathol. 2007; 58(1):41-50. View

Madrid M, Lo R . Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status. Breast Cancer Res. 2004; 6(5):R593-600. PMC: 549176. DOI: 10.1186/bcr915. View

Dietel M, Ellis I, Hofler H, Kreipe H, Moch H, Dankof A . Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of.... Virchows Arch. 2007; 451(1):19-25. DOI: 10.1007/s00428-007-0424-5. View

Pothos A, Plastira K, Plastiras A, Vlachodimitropoulos D, Goutas N, Angelopoulou R . Comparison of chromogenic in situ hybridisation with fluorescence in situ hybridisation and immunohistochemistry for the assessment of her-2/neu oncogene in archival material of breast carcinoma. Acta Histochem Cytochem. 2008; 41(3):59-64. PMC: 2447915. DOI: 10.1267/ahc.07029. View

Todorovic-Rakovic N, Jovanovic D, Neskovic-Konstantinovic Z, Nikolic-Vukosavljevic D . Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer. Pathol Int. 2005; 55(6):318-23. DOI: 10.1111/j.1440-1827.2005.01831.x. View

Bartlett J, Munro A, Dunn J, McConkey C, Jordan S, Twelves C . Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 2010; 11(3):266-74. DOI: 10.1016/S1470-2045(10)70006-1. View

Hauser-Kronberger C, Dandachi N . Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer. J Mol Histol. 2004; 35(6):647-53. DOI: 10.1007/s10735-004-2186-6. View

10.

Peiro G, Mayr D, Hillemanns P, Lohrs U, Diebold J . Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome. Mod Pathol. 2004; 17(3):227-87. DOI: 10.1038/modpathol.3800006. View

11.

Sapino A . [Diagnostic process in breast carcinoma: role of core biopsy and needle aspiration of axillary lymph nodes]. Pathologica. 2004; 95(5):258-9. View

12.

Lin F, Shen T, Prichard J . Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens. Diagn Cytopathol. 2005; 33(6):376-80. DOI: 10.1002/dc.20401. View

13.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

14.

Bilous M, Morey A, Armes J, Cummings M, Francis G . Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry. Pathology. 2006; 38(2):120-4. DOI: 10.1080/00313020600561518. View

15.

Peiro G, Aranda F, Adrover E, Niveiro M, Alenda C, Paya A . Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance. Hum Pathol. 2006; 38(1):26-34. DOI: 10.1016/j.humpath.2006.07.013. View

16.

Vera-Roman J, Rubio-Martinez L . Comparative assays for the HER-2/neu oncogene status in breast cancer. Arch Pathol Lab Med. 2004; 128(6):627-33. DOI: 10.5858/2004-128-627-CAFTNO. View

17.

Ni R, Mulligan A, Have C, OMalley F . PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer. Appl Immunohistochem Mol Morphol. 2007; 15(3):316-24. DOI: 10.1097/01.pai.0000213138.01536.2e. View

18.

Nunes C, Rocha R, Reis-Filho J, Lambros M, Rocha G, Sanches F . Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas. J Clin Pathol. 2008; 61(8):934-8. DOI: 10.1136/jcp.2007.053892. View

19.

Moelans C, de Weger R, van Blokland M, Ezendam C, Elshof S, Tilanus M . HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization. Cell Oncol. 2008; 31(1):1-10. PMC: 4618800. DOI: 10.3233/clo-2009-0461. View

20.

Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A . c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol. 1996; 14(10):2702-8. DOI: 10.1200/JCO.1996.14.10.2702. View